Protagonist Therapeutics, Inc. (PTGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - Protagonist Therapeutics is poised for significant growth and value creation over the next 12 to 24 months, driven by two potential blockbuster drug approvals and launches, multiple clinical readouts, new discovery programs, and a strong cash position [3] Company Overview - Protagonist Therapeutics is participating in the 44th JPMorgan Healthcare Conference for the sixth consecutive year, indicating its established presence in the biotech sector [2] - The company is focused on completing a decade-long journey from concept to commercialization with two specific assets: icotrokinra, partnered with Johnson & Johnson, and rusfertide, partnered with Takeda [3] Development Pipeline - The company is highlighting its development candidates that target validated biological pathways, with differentiated assets aimed at addressing specific unmet medical needs across multiple indications [4]